Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06639607
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-07
Brief Title:
PEP-CMV Nivolumab for Newly Diagnosed Diffuse Midline GliomaHigh-grade Glioma and Recurrent Diffuse Midline GliomaHigh-grade Glioma Medulloblastoma and Ependymoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 12 Trial of PEP-CMV Nivolumab for Newly Diagnosed Diffuse Midline GliomaHigh-grade Glioma and Recurrent Diffuse Midline GliomaHigh-grade Glioma Medulloblastoma and Ependymoma PRiME II
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PRiME II
Brief Summary:
This is a multisite phase III clinical trial in children and young adults with newly-diagnosed high-grade glioma HGG diffuse midline glioma DMG and recurrent HGGDMG Medulloblastoma MB or ependymoma EPN to determine the safety immunogenicity and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None